Impact of previous disease-modifying treatment on effectiveness and safety outcomes, among patients with multiple sclerosis treated with alemtuzumab

OBJECTIVES: Alemtuzumab is effective in patients with active multiple sclerosis but has a complex safety profile, including the development of secondary autoimmunity. Most of patients enrolled in randomised clinical trials with alemtuzumab were either treatment naïve or pretreated with injectable su...

Descripción completa

Detalles Bibliográficos
Autores principales: Pfeuffer, Steffen, Ruck, Tobias, Pul, Refik, Rolfes, Leoni, Korsukewitz, Catharina, Pawlitzki, Marc, Wildemann, Brigitte, Klotz, Luisa, Kleinschnitz, Christoph, Scalfari, Antonio, Wiendl, Heinz, Meuth, Sven G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Multiple Sclerosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8372391/
https://www.ncbi.nlm.nih.gov/pubmed/33712515
http://dx.doi.org/10.1136/jnnp-2020-325304

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8372391/
https://www.ncbi.nlm.nih.gov/pubmed/33712515
http://dx.doi.org/10.1136/jnnp-2020-325304

Ejemplares similares